Illustration for: Thatch Hits Unicorn Status As Health Costs Surge

Thatch Hits Unicorn Status As Health Costs Surge

Thatch, an ICHRA marketplace that lets employers fund individual health plans instead of one group policy, raised a $108 million Series C at a $1 billion valuation as revenue grew nearly sevenfold over the past year.

By the Numbers

$108M
Series C
$1B
Valuation
$40M
Prior Series B (Apr 2025)
Oct 2021
Founded
5,000+
Employers on platform
TC
By the Funding Desk
Edited by Trace Cohen · Early-stage VC & angel · Founder, New York Venture Partners
2 min read
ShareXLinkedInEmail

THE RUNDOWN

1

Thatch's model relies on ICHRA, a mechanism federal regulation created in 2020 that lets employers fund individual insurance plans instead of enrolling everyone in one company-wide policy -- the round is a bet that a five-year-old regulatory carve-out is becoming the default rather than a niche option.

2

Revenue growing nearly sevenfold in a single year, alongside more than 5,000 employers now on the platform, is unusually fast expansion for benefits infrastructure, a category that normally moves at the pace of annual open-enrollment cycles rather than software adoption curves.

3

The investor list -- Eli Lilly, ADP Ventures and Paychex alongside General Catalyst, Index Ventures and a16z -- mixes pharma and payroll-incumbent strategic money with traditional venture capital, suggesting Thatch is being underwritten as distribution infrastructure, not just another benefits app.

4

Employer health costs rising is the tailwind and also the risk: Thatch's pitch gets stronger every year premiums climb, but a market correction in healthcare cost growth, or a federal rule change to ICHRA itself, would remove the exact pressure driving employer adoption.

TC

The VC Read · Trace's Take

Trace Cohen

The regulatory dependency here is the real diligence item, not the growth rate. ICHRA is a five-year-old rule, not a law, and Thatch's entire addressable market grows or shrinks with how aggressively employers adopt it -- ask how much of that sevenfold revenue growth is net-new employer logos versus existing employers expanding seats, because those are very different quality of growth at a $1 billion mark. Eli Lilly in the cap table is worth watching for a pharma-benefits integration play nobody's talking about yet.

Analysis

Thatch raised a $108 million Series C at a $1 billion valuation, TechCrunch reported, with the round led by The General Partnership, Index Ventures, General Catalyst and Andreessen Horowitz. Strategic investors ADP Ventures, Paychex, Eli Lilly and Company, Scale Venture Partners, QuantumLight, SemperVirens, Quiet Capital and Avid Ventures also participated -- a mix of payroll incumbents and a major pharmaceutical company alongside the traditional venture backers.

Founded in San Francisco in October 2021 by chief executive Chris Ellis and president Adam Stevenson, Thatch sells an ICHRA marketplace -- Individual Coverage Health Reimbursement Arrangement, a mechanism created by federal regulation in 2020 that lets a company set a fixed pre-tax health budget per employee instead of enrolling everyone in a single group plan. Workers then use those funds to choose among dozens of health, dental and vision plans on Thatch's marketplace, with the company using AI to recommend a plan suited to each employee's needs. Both founders have said they were drawn to the problem after each lost a parent to cancer and experienced firsthand how confusing and rigid group health coverage can be during a health crisis.

Growth On Top Of A Regulatory Carve-Out

The company says revenue has grown nearly sevenfold over the past twelve months and that more than 5,000 employers now use the platform to move away from traditional group health plans. That growth rate follows a $40 million Series B the company raised in April 2025, meaning Thatch has now raised three rounds inside roughly eighteen months as employer interest in ICHRA has accelerated alongside rising healthcare costs. The closest adjacent player in individual-plan enrollment is HealthSherpa, though Thatch's pitch is aimed specifically at the employer-benefits administration layer rather than direct-to-consumer plan shopping.

The regulatory dependency is the detail worth sitting with. ICHRA exists because of a 2020 rule change under the first Trump administration, and its adoption has been gradual rather than universal -- most employers still default to traditional group plans, and Thatch's total addressable market is a function of how many companies actually switch models rather than how good Thatch's software is. That is a real tailwind today: employer group-plan premiums have climbed steadily for years, and ICHRA's individual-market flexibility becomes more attractive to a cost-conscious CFO with every renewal cycle that brings a double-digit premium increase. It is also a risk, because the same regulatory mechanism that created Thatch's market could in principle be narrowed by a future rule change, and demand tied this directly to a specific cost trend can soften if that trend moderates.

For a company now valued at $1 billion on $108 million raised in its Series C alone, the number that will matter most at the next round is retention through a full renewal cycle -- whether the 5,000 employers who adopted ICHRA through Thatch during a period of rising costs stay on the platform if premium growth ever slows, or whether some fraction reverts to the administrative simplicity of a single group plan once the cost pressure that drove them to switch eases.

ShareXLinkedInEmail

Key Sources

2 sources

Reported by TechCrunch · Analysis by Value Add Pulse.

← Back to Pulse

THE WIRE in your inbox— Tech, startup & VC news with Trace's take. Free, no spam.